TickerFacts.

Repligen Corp (RGEN): Share Repurchases

Annual figures by period end, from SEC filings.

$0
Year ended 2025-12-31
$14.39M2021-12-31: $02022-12-31: $02023-12-31: $14.39M2024-12-31: $02025-12-31: $0$0
2021-12-31 Share Repurchases (USD) 2025-12-31
Period endedShare RepurchasesChange YoYSource filing
2025-12-31$0n/a2026-02-26, From 2025-01-01
2024-12-31$0-100.0%2026-02-26, From 2024-01-01
2023-12-31$14.39Mn/a2026-02-26, From 2023-01-01
2022-12-31$0n/a2025-03-14, From 2022-01-01
2021-12-31$0n/a2024-11-18, From 2021-01-01

Share Repurchases at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShare RepurchasesChange YoY
Repligen Corp (RGEN)2025-12-31$0n/a
ADMA Biologics, Inc. (ADMA)2025-12-31$31.94Mn/a
Bio-Techne Corp (TECH)2026-06-30$41.67M-84.9%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$342.37M+36.9%
Moderna, Inc. (MRNA)2025-12-31$2.00Mn/a
Qiagen N.V. (QGEN)2025-12-31$280.09M-4.1%
Exelixis, Inc. (EXEL)2026-01-02$947.51M+45.3%
Neurocrine Biosciences Inc (NBIX)2025-12-31$167.70M-44.1%
Champions Oncology, Inc. (CSBR)2025-04-30$0-100.0%

Compare RGEN, ADMA, TECH, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗